Nuvalent (NUVL) Preferred Stock Liabilities (2020 - 2021)
Nuvalent (NUVL) reported Preferred Stock Liabilities of $185.4 million for Q2 2021, up 641.36% on a YoY basis from $25.0 million in Q2 2020, and up 265.27% quarter-over-quarter from $50.8 million in Q1 2021.
Nuvalent (NUVL) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Nuvalent has reported Preferred Stock Liabilities for 2 years, with the latest figure at $185.4 million in Q2 2021.
- For the quarter ending Q2 2021, Preferred Stock Liabilities rose 641.36% year-over-year to $185.4 million; the trailing twelve-month figure through Jun 2021 stood at $185.4 million (up 641.36% YoY), and the FY2020 full-year result was $35.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2021 stood at $185.4 million, up from $50.8 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $185.4 million in Q2 2021, with the low at $25.0 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 185.41 Mn |
| Mar 31, 2021 | 50.76 Mn |
| Dec 31, 2020 | 35.35 Mn |
| Sep 30, 2020 | 35.35 Mn |
| Jun 30, 2020 | 25.01 Mn |